Wren Laboratories

Wren Laboratories is a pioneering diagnostics company specializing in mRNA-based liquid biopsy for oncology. Its core innovation is a proprietary RNA stabilization and testing platform that profiles multi-gene mRNA expression to detect active signaling pathways in tumors, offering insights for personalized cancer management and drug development. The company has launched two clinically validated tests, NETest® for neuroendocrine tumors and PROSTest® for prostate cancer, and is supported by an extensive intellectual property portfolio and numerous peer-reviewed publications. It operates as a certified laboratory service provider, serving both clinicians and biopharma partners.

Proprietary blood-based liquid biopsy platform focusing on multi-gene messenger RNA (mRNA) expression profiling. It uses RNA stabilization and machine learning to analyze active signaling pathways in tumors, providing a functional view of cancer biology beyond DNA mutation detection.

Wren competes in the liquid biopsy space against major players like Guardant Health, Foundation Medicine, and Natera, which primarily use ctDNA and NGS. Its key differentiation is the focus on mRNA expression for functional insights, a niche with fewer direct competitors but requiring education to shift the clinical paradigm from mutation detection to activity monitoring.